Ono Pharmaceutical Co., Ltd.
ONO PHARMA USA is the US subsidiary of ONO PHARMACEUTICAL CO, LTD., an R&D-oriented pharmaceutical company founded in 1717, with headquarters in Osaka, Japan. For over 300 years, ONO has been committed to delivering novel medicines to patients with high unmet medical need. Our passion has led to first-in-class therapies including the world’s first chemically synthesized prostaglandins as well as nivolumab, the world’s first anti-PD-1 antibody. These drugs have changed the treatment paradigm and outlook for millions of people globally. Today, ONO has a growing pipeline of innovative therapeutics across four focus areas: oncology, immunology, neurology, and specialty medicine. ONO is committed to Challenging the Unknown, relentlessly pursuing research that will bring safe and effective solutions to more patients around the world. For information on our community guidelines, visit: http://bit.ly/43MdR0Swww.ono-pharma.com
3
MENTIONS
3
EPISODES
3
PODCASTS
Search complete. 3 mentions across 3 episodes found for "Ono Pharmaceutical Co., Ltd.".
Sep 17, 2026
speaker_0HOST
These therapies represent a revolutionary approach in personalized medicine for cancer treatment, with Legend positioning itself for growth and innovation.
speaker_0HOST
Bristol Myers Squibb and Ono Pharmaceutical are preparing to contest Amgen's efforts to launch a biosimilar for their oncology blockbuster Opdivo.
speaker_0HOST
This reflects broader competitive dynamics within the biologics market where biosimilars promise more cost-effective options, potentially reshaping market shares and pricing strategies.
speaker_0HOST
Manufacturing innovations are also at play with Ori Biotech securing a one hundred twenty million dollars deal for an automated production platform in cell therapy manufacturing.
Jack SilbersteinGUEST
That was sponsored by Mission Biocapita.
Jack SilbersteinGUEST
Mission BioCapital, Eli Lilly, and Ono Pharma.
Jack SilbersteinGUEST
And then we've also won an award just this past spring from the American Cancer Society.
Jack SilbersteinGUEST
And so really, we've been very fortunate to win a lot of awards.
speaker_0NARRATOR
This activity is developed with our educational partner, Sarcoma Alliance for Research through collaboration.
speaker_0NARRATOR
This activity is supported by independent educational grants from DeCifra Pharmaceuticals, a member of Ono Pharma and Merck KGAA, Darmstadt, Germany.
speaker_0NARRATOR
To access all materials for this activity, visit peerview.com slash GGN 860.